Detection of Early Esophageal Neoplastic Barrett Lesions with Quantified Fluorescence Molecular Endoscopy Using Cetuximab-800CW.
Barrett esophagus
cetuximab
epidermal growth factor receptor
esophageal adenocarcinoma
fluorescence molecular imaging
Journal
Journal of nuclear medicine : official publication, Society of Nuclear Medicine
ISSN: 1535-5667
Titre abrégé: J Nucl Med
Pays: United States
ID NLM: 0217410
Informations de publication
Date de publication:
05 2023
05 2023
Historique:
received:
13
07
2022
revised:
06
12
2022
medline:
1
5
2023
pubmed:
6
1
2023
entrez:
5
1
2023
Statut:
ppublish
Résumé
Esophageal adenocarcinoma causes 6% of cancer-related deaths worldwide. Near-infrared fluorescence molecular endoscopy (NIR-FME) uses a tracer that targets overexpressed proteins. In this study, we aimed to investigate the feasibility of an epidermal growth factor receptor (EGFR)-targeted tracer, cetuximab-800CW, to improve detection of early-stage esophageal adenocarcinoma.
Identifiants
pubmed: 36604181
pii: jnumed.122.264656
doi: 10.2967/jnumed.122.264656
doi:
Substances chimiques
Cetuximab
PQX0D8J21J
ErbB Receptors
EC 2.7.10.1
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
803-808Informations de copyright
© 2023 by the Society of Nuclear Medicine and Molecular Imaging.